1. Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study.
- Author
-
Demel, Ivo, Skopal, David, Šafránková, Eliška, Rozsívalová, Petra, Jindra, Pavel, Šrámek, Jiří, Turková, Adéla, Vydra, Jan, Labská, Klára, Vedrová, Jana, Čerňan, Martin, Szotkowski, Tomáš, Móciková, Heidi, Hynková, Lenka, Šušol, Ondrej, Kováčová, Ingrid, Belada, David, and Hájek, Roman
- Subjects
SARS-CoV-2 ,PRE-exposure prophylaxis ,HIV seroconversion ,CORONAVIRUS diseases ,HEMATOPOIETIC stem cell transplantation ,HEMATOLOGIC malignancies ,SARS-CoV-2 Omicron variant - Abstract
Despite lower virulence, the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) still poses a relevant threat for immunocompromised patients. A retrospective multicentric study was conducted to evaluate the efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) with a 6-month follow-up for preventing severe COVID-19 in adult patients with hematology malignancy. Among the 606 patients in the cohort, 96 (16%) contracted COVID-19 with a median of 98.5 days after Evusheld administration. A total of 75% of patients had asymptomatic or mild severity of COVID-19, while just 25% of patients with SARS-CoV-2 positivity had to be hospitalized. Two patients (2%) died directly, and one patient (1%) in association with COVID-19. Eight patients (1.3%) of every cohort experienced adverse events related to Evusheld, mostly grade 1 and of reversible character. It was found that complete vaccination status or positive seroconversion was not associated with lower risk of COVID-19 infection. Previous treatment with an anti-CD20 monoclonal antibody was associated with higher rates of COVID-19, while previous treatment with anti-CD38 monoclonal antibody was not, as was the case for recipients of hematopoietic stem cell transplantation or CAR-T cell therapy. Presence of other comorbidities was not associated with more severe COVID-19. The results support the growing evidence for Evusheld's efficacy against severe COVID-19 in patients with hematology malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF